Sushmi Dey

All stories by Sushmi Dey

All life-saving drugs may come under price cap

All life-saving drugs may come under price cap

Rediff.com25 Oct 2014

NPPA suggests expanding the list of essential medicines whose prices are controlled

Ranbaxy staff get pay-cut shield in Sun buyout

Ranbaxy staff get pay-cut shield in Sun buyout

Rediff.com20 Oct 2014

Sun maintained it would retain the best of both organisations to build a global pharma company.

Ranbaxy's top executives in the US resign

Ranbaxy's top executives in the US resign

Rediff.com14 Oct 2014

US country head, key departmental heads leave; more likely to follow.

Is India ready to fight Ebola? NO WAY!

Is India ready to fight Ebola? NO WAY!

Rediff.com10 Oct 2014

No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.

Pharma firms to be hit as drug regulator caps prices

Pharma firms to be hit as drug regulator caps prices

Rediff.com19 Sep 2014

Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries

Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countries

Rediff.com15 Sep 2014

Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.

Sun Pharma draws up plan to fix ailing Ranbaxy

Sun Pharma draws up plan to fix ailing Ranbaxy

Rediff.com12 Sep 2014

It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues

Drug price monitoring cells across states soon

Drug price monitoring cells across states soon

Rediff.com8 Sep 2014

The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.

FDI policy for medical devices on the cards

FDI policy for medical devices on the cards

Rediff.com31 Aug 2014

Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.

Another big blow for Ranbaxy

Another big blow for Ranbaxy

Rediff.com22 Aug 2014

Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.

US FDA India head quits; regulator goes for rejig

US FDA India head quits; regulator goes for rejig

Rediff.com21 Jul 2014

Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.

Sun, Ranbaxy hire Mckinsey for merger assistance

Sun, Ranbaxy hire Mckinsey for merger assistance

Rediff.com18 Jul 2014

Sun-Ranbaxy are keen to complete the merger process.

Drug makers seek out-of-court settlement in clinical trial cases

Drug makers seek out-of-court settlement in clinical trial cases

Rediff.com10 Jun 2014

In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.

Drug makers told to give pricing details in 10 days

Drug makers told to give pricing details in 10 days

Rediff.com6 Jun 2014

The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.

Now, buy medicines and stents on EMI

Now, buy medicines and stents on EMI

Rediff.com5 Jun 2014

The company did not respond to specific queries on the project's expansion.

Indian drug cos to benefit as US expedites generic clearances

Indian drug cos to benefit as US expedites generic clearances

Rediff.com12 May 2014

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Novartis-Glaxo deal signals pharma firms don't have it easy

Novartis-Glaxo deal signals pharma firms don't have it easy

Rediff.com24 Apr 2014

Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.

Novartis-GSK-Eli Lilly deal may affect Indian market

Novartis-GSK-Eli Lilly deal may affect Indian market

Rediff.com23 Apr 2014

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

ICAI to ban three auditors in Satyam case

ICAI to ban three auditors in Satyam case

Rediff.com23 Apr 2014

ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.

Ranbaxy buy in line with Sun's strategy

Ranbaxy buy in line with Sun's strategy

Rediff.com17 Apr 2014

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.

Regulatory pain for GSK's Crocin Advance

Regulatory pain for GSK's Crocin Advance

Rediff.com28 Mar 2014

The NPPA letter was issued to GSK on Wednesday.

Consumers may have to pay more for insulin

Consumers may have to pay more for insulin

Rediff.com21 Mar 2014

Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.

24 private hospitals get showcause notices

24 private hospitals get showcause notices

Rediff.com20 Mar 2014

What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.

Why is Novartis likely to lose Tiamulin drug licence?

Why is Novartis likely to lose Tiamulin drug licence?

Rediff.com19 Mar 2014

Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.

US regulator urges USV to probe staff for inaccurate data reporting

US regulator urges USV to probe staff for inaccurate data reporting

Rediff.com5 Mar 2014

The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.

Why is DLF again under competition watchdog's scanner?

Why is DLF again under competition watchdog's scanner?

Rediff.com4 Mar 2014

CCI has accused realty player DLF of preparing one-sided agreement with home buyers

Ranbaxy whistle-blower to talk on quality of Made-in-India drugs

Ranbaxy whistle-blower to talk on quality of Made-in-India drugs

Rediff.com27 Feb 2014

Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.

Scanner on Novartis for giving 'fake' documents

Scanner on Novartis for giving 'fake' documents

Rediff.com10 Feb 2014

Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.

After ban on drug facilities, US regulator comes calling

After ban on drug facilities, US regulator comes calling

Rediff.com10 Feb 2014

Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.

US FDA's action triggers internal conflict at Ranbaxy plant

US FDA's action triggers internal conflict at Ranbaxy plant

Rediff.com1 Feb 2014

Ranbaxy is facing trouble with its leadership, which has allegedly failed to reach out to its employees working on the ground.

Indian drug regulator threatens to ban Ranbaxy

Indian drug regulator threatens to ban Ranbaxy

Rediff.com29 Jan 2014

A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.

Drug regulator lets pharma firms fix own penalty

Drug regulator lets pharma firms fix own penalty

Rediff.com20 Jan 2014

Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.

After Ajay Devgn, Kamal Haasan approaches CCI

After Ajay Devgn, Kamal Haasan approaches CCI

Rediff.com14 Jan 2014

Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.

Wockhardt's review petitions on drug pricing rejected

Wockhardt's review petitions on drug pricing rejected

Rediff.com13 Jan 2014

Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.

Nestle's cumin extract patent bid raises hackles

Nestle's cumin extract patent bid raises hackles

Rediff.com8 Jan 2014

Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.

Wockhardt's Shendra unit set for key US test

Wockhardt's Shendra unit set for key US test

Rediff.com7 Jan 2014

If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.

Repackaged drugs likely to be labelled 'new'

Repackaged drugs likely to be labelled 'new'

Rediff.com2 Jan 2014

Roadblocks ahead as these medicines could face new clinical tests, more scrutiny

US FDA likely to inspect new Visakhapatnam arm of Divi's Labs in Jan

US FDA likely to inspect new Visakhapatnam arm of Divi's Labs in Jan

Rediff.com31 Dec 2013

The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.

Local drug makers worried as regulators start working together

Local drug makers worried as regulators start working together

Rediff.com26 Dec 2013

Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.

Pharma firms might resume sales of analgin-based drugs

Pharma firms might resume sales of analgin-based drugs

Rediff.com24 Dec 2013

The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.

Next